Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Discovery & Translation

Wave takes its next-gen oligos beyond gene silencing and splicing

Preclinical data suggest the oligos can be used for base editing and modulating protein-protein interactions

March 9, 2022 1:42 AM UTC

Having leveraged lessons from failed clinical trials to optimize its next-generation of chemically modified oligonucleotides, Wave has now shown it can apply the oligos in new ways, adding RNA base editing and modulation of protein-protein interactions to the types of therapeutic interventions the company can pursue.

After splashing onto the scene in 2015 with a platform to bring stereopurity, already common in the small molecule world, to oligonucleotide therapies, Wave Life Sciences Ltd. (NASDAQ:WVE) was beset by clinical setbacks that sent it back to the preclinical drawing board to optimize various properties of its compounds.  ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article